Stem Cell and PRP Injections for Knee Arthritis: What They Can and Cannot Do

Neither stem cell nor PRP injections can regrow cartilage that has already worn away. PRP genuinely helps a narrow group of people with early damage, and international guidelines still describe the evidence as unsettled. In India, stem cell treatment outside the approved list is now restricted to registered clinical trials. Most people who try these routes for advanced arthritis spend a great deal and end up where they started.

Been advised stem cell or PRP injections? Send us your X-ray or MRI to find out what stage you are actually at — free.

Free Report Review

First, Why the Offer Is So Convincing

Before anything else, it is worth saying that if you were tempted by this, you were not being foolish.

You have been told your knee is worn out. You have been told the answer is an operation that costs two or three lakh, involves a hospital stay, and takes months to recover from. And then someone tells you there is another way: no surgery, no hospital, no cutting, using your own cells, and your knee can heal itself.

That is the most attractive offer in orthopaedics. It is why the market for it is so large, and why it is sold so confidently. The problem is not that patients are gullible. It is that the promise is wonderful and the evidence behind it is much smaller than the promise.

Can These Injections Regrow the Cartilage in My Knee?

No treatment available today regrows a worn joint surface back to normal. Once the cartilage has gone across a part of the knee, what is realistically achievable is controlling the pain, keeping you moving, and slowing things down.

If a clinic tells you that grade 4 arthritis will become grade 1, or that a bow-legged knee will straighten with injections, they are describing something that has not been shown to happen. That is the clearest test you can apply, and you can apply it without any medical knowledge at all.

What Is Actually in the Syringe?

Three quite different things get called by similar names, and the differences matter enormously:

1. PRP (Platelet-Rich Plasma): Blood is taken from your arm, spun in a centrifuge to concentrate the platelets and growth factors, and injected back into your knee in the same sitting. It is your own blood, minutes old. It is an autologous blood fraction, not a stem cell treatment at all.

2. Same-Day "Stem Cell" Aspirate: Fat (adipose tissue) or bone marrow is aspirated from your body, processed briefly in a clinic centrifuge, and injected back. It is quick, it is your own tissue, but what is actually in it varies enormously from patient to patient. It contains very few actual stem cells and is not a standardized or manufactured drug product.

3. A Licensed Cell Product: Living mesenchymal stromal cells grown, purified, and manufactured under strict pharmaceutical drug regulations, evaluated in formal clinical trials, and approved by the national drug controller at a defined dosage. There is currently one such approved product in India for knee osteoarthritis (Stempeucel). It is not what ordinary private clinics are drawing and injecting in an afternoon.

All three get loosely marketed to patients as "stem cell therapy". Only the third has undergone the regulatory scrutiny that the phrase implies.

What Does Indian Law Allow Now?

The regulatory and legal landscape changed materially in 2026, and most patients have not been informed:

• Supreme Court Judgment (January 2026): In Yash Charitable Trust v. Union of India, the Supreme Court ruled on the commercial offering of stem cell treatments outside clinical trials. The Court held that where a therapy has not been established as accepted standard medical practice, it can only be administered within approved, monitored clinical trials. Offering unproven stem cell therapies as routine clinical care falls below the medical standard of care.

• National Medical Commission Advisory (March 2026): Following an ICMR directive, the NMC issued a national advisory reiterating that stem cell therapy in routine practice is strictly restricted to government-approved indications (such as hematopoietic stem cell transplants for blood disorders). Any use beyond that requires ICMR ethical clearance and prior CDSCO or DHR regulatory approval.

📌 What to do: Before paying for any stem cell procedure, ask one question in writing: "Which government-approved indication does this fall under, or which registered CTRI trial am I joining?" A legitimate clinical provider will provide documentation immediately.

So Is PRP a Waste of Money?

No, and it would be as dishonest to dismiss it entirely as to oversell it.

PRP sits in a separate category from stem cells. The international consensus is genuinely unsettled rather than negative. A comprehensive review of international orthopaedic clinical practice guidelines found that evidence is currently insufficient to issue a definitive recommendation either for or against PRP in knee osteoarthritis. It may modulate local inflammation, but it is not a structural cure.

Where PRP is most likely to help is in a very specific patient profile:

• Cartilage is thinning (early Grade 1 or 2) rather than completely worn down to bone.

• Damage is focal and localized, not widespread across the entire joint.

• Symptoms began recently (within the last 6 months) rather than persisting for years.

• The leg alignment is normal, with no significant varus (bow-legged) deformity.

• The patient is relatively younger and active, rather than managing late-stage disease.

If you match that profile, a supervised trial of PRP can provide temporary symptom relief. If you have bone-on-bone Grade 4 arthritis, PRP will not prevent surgical joint reconstruction.

What Do These Treatments Cost?

A PRP injection session typically costs ₹25,000 to ₹30,000 per sitting in private clinics, commonly marketed as a package of 2 to 3 sessions (₹50,000–₹90,000). Stem cell packages range anywhere from ₹1 lakh to ₹2.5 lakh over several months.

⚠️ The economics of PRP: PRP has virtually zero material cost. The biological source is your own blood, and the only consumables are a collection tube, a syringe, and a centrifuge spin. The price is not anchored to production costs; it is set by what the emotional promise of avoiding surgery is worth to an anxious patient.

What We See When People Come to Us Afterwards

Across our network's orthopaedic outpatient clinics, roughly 7 out of 10 patients presenting for surgical evaluation have already spent between ₹1.5 lakh and ₹2.5 lakh over the preceding 12 to 18 months on regenerative packages, unproven cell injections, or alternative therapies promising cartilage reversal.

This pattern has two significant clinical consequences:

1. The financial expenditure on ineffective injections often equals or exceeds the entire package cost of standard knee replacement surgery.

2. The 12 months spent waiting for cartilage to regrow is a year of reduced mobility, quadriceps muscle wasting, and progressive joint stiffness — making post-surgical rehabilitation more difficult than it needed to be.

Get an objective knee care roadmap with every treatment option ranked for your specific X-ray grade.

Get Care Plan — ₹999

What Does Have Better Evidence?

Conventional medical options are not miraculous cures either, but their efficacy and timelines are well documented:

Treatment Option Where the Evidence Stands What to Realistically Expect Targeted exercise & weight loss Recommended across all major international orthopaedic guidelines The single most cost-effective intervention; reduces joint load by 4 kg for every 1 kg of body weight lost Corticosteroid injection Accepted for acute, short-term flare-ups Rapid anti-inflammatory relief within days; typically lasts 6 to 12 weeks; not a long-term solution Hyaluronic acid (Viscosupplementation) Conditional / variable guideline support; not recommended for routine use by AAOS Slower onset than steroids; provides lubricating shock absorption in mild-to-moderate arthritis; does not regrow cartilage Cooled radiofrequency ablation (Cooled RFA) Supported for medically unfit patients or those declining surgery Stops sensory nerve pain signals from the joint; delivers 70–80% relief for 1 to 2 years; leaves joint structure intact Realignment surgery (High Tibial Osteotomy) Well established for unicompartmental arthritis with varus deformity Shifts weight away from the damaged compartment to preserve the natural joint in active patients under 60 Partial or total knee replacement Gold standard definitive treatment for end-stage Grade 4 arthritis Replaces worn articular surfaces with certified implants; predictable long-term pain relief and functional restoration

Six Questions That Separate a Real Offer From a Sales Pitch

1. Which government-approved medical indication does this injection fall under, or which registered clinical trial am I joining?

2. What specific biological material is in the syringe, and is it a CDSCO-approved manufactured drug or a clinic aspirate?

3. For someone at my exact X-ray grade, how much pain reduction is clinically documented, and for how many months?

4. What is the medical plan if this injection fails to provide relief after 8 weeks?

5. Is this billed as a single procedure or an open-ended package, and what is the total out-of-pocket expenditure?

6. Will my standing X-ray grade or joint space show any visible structural improvement afterwards?

📌 The truthful answer to Question 6 is always No. If a provider claims your X-ray will show restored cartilage space, you can immediately evaluate the validity of their other answers.

If You Have Already Spent Money on This

You almost certainly have not suffered physical harm, and it is important to state that plainly because patients carry unnecessary guilt. What was expended was time and money. Neither is recovered by regretting it.

The most constructive next step is simple: determine your exact arthritis grade through a standing weight-bearing X-ray. Almost every suboptimal decision in orthopaedics stems from ambiguity around the true baseline: early stages are pushed prematurely toward surgery, while advanced stages are sold expensive injections that have zero physiological chance of success.

Clinical & Legal References

1. Supreme Court of India Ruling: Yash Charitable Trust v. Union of India (Decided 30 January 2026), restricting the commercial application of unproven stem cell therapies outside monitored clinical trials.

2. National Medical Commission Advisory: NMC Guidelines on Stem Cell Therapy (March 2026), restricting routine clinical administration to recognized hematopoietic indications.

3. CDSCO Regulatory Status: Regulatory approval and marketing authorisation for licensed stem cell products in India.

4. International Guidelines Review: Comprehensive meta-review of orthopaedic society guidelines evaluating PRP recommendations in knee osteoarthritis.

5. AAOS Clinical Practice Guidelines (2021): American Academy of Orthopaedic Surgeons management guidelines on non-operative knee osteoarthritis care.

Conclusion: Clarity Before Spending

Knee arthritis care should be dictated by radiological evidence, not commercial salesmanship. At MyDocsy, our care navigation team helps you:

• Get an objective grading of your knee condition from high-resolution weight-bearing scans.

• Understand the exact success rates of PRP, radiofrequency ablation, and surgical options for your grade.

• Avoid unproven regenerative packages that drain your healthcare savings without solving the problem.

• Connect directly with ethical orthopaedic surgeons and non-surgical pain specialists across Mumbai and Pune.

My Surgery Only at MyDocsy. My Care Only at MyDocsy. Schedule a free consultation with a Care Navigator today.

Speak with a Care Navigator